Abstract:Background China’s pharmaceutical market is growing at a healthy pace. This is due to potential rising per capita income, an increasing elderly population, urbanisation demographics and more access to health care. Methodology The methodology used is a comparative study on the basis of original empirical research. More specifically, the part of examination facts and regulation has been written by conducting empirical research on current international and national resource concerning the subject from books, various guidelines, rules and regulation, articles, published reports and internet. Results Generally the regulatory environment in China has been considered as an very challenging one. From regulatory perspective, CFDA regulations have not been stringent enough nor has it been robust enough to create a quality supply of medications, with (1) concerns in the subject matter, quality comparison between international regulatory standard and usually accepted local products and manufactures set standards; (2) a timeline for regulatory assessment and authorization of new drugs which is much longer in comparison to most countries; (3) less number of regulatory reviewer which has led to a backlog of earlier application. The journey to reshape China from ‘made-in-China’ to ‘discovered-in-China’ is highly challenging. (4) Complications with local protection, corruption and a lack of transparency. The directives from Government has recognized the need for significant system-level transformations for streamlining the pharmaceutical regulatory environment. Conclusion Continuing on the route of reform is promising that all Chinese citizens is eventually having access to safe, effective and high-quality medications in affordable price. These reformations are encouraging and promising not only for China’s health care system, but also for global Pharmaceutical industry and that’s the reason, now many big Pharma companies are considering China as a prime focus. The companies need to make use of the new opportunities, accessible to experience the benefit of faster time-to-market, and cause rewarding growth prospect for both domestic/ multinational companies.

Regulation of Generic Drugs in China: Progress and Effect of the Reform of the Review and Approval System

Trends and Characteristics of New Drug Approvals in China, 2011–2021

Influence of Chemical Drug Registration Reform on Pharmaceutical Industry in China

Improving access to domestic innovative medicines: characteristics and trends of approved drugs in China 2010-2024

Approvals of Pharmaceutical Drugs in China in the Post-Drug Registration Regulation II Era.

Recent Advances in Drug Development and Regulatory Science in China

Research on Approval and Regulatory System of Generics in USA

Reforming China's drug regulatory system

The New Drug Conditional Approval Process in China: Challenges and Opportunities

Evolution of drug regulations and regulatory innovation for anticancer drugs in China

On the Amendments of China’s Provisions for Drug Registration

Drug policy in China. Transformations, current status and future prospects

Overview of Drug Evaluation System in China

Review of Registration and Patent of Category 1.1 Chemical Drugs in China between October 2007 and September 2014

An empirical study of the impact of generic drug competition on drug market prices in China

Overview on the Amendments of Provisions for Drug Registration in China

Tailored to fit: China optimizes policies and regulations regarding drug registration and review to promote innovation in traditional Chinese medicine

Regulatory watch: Innovative drug availability in China.

Challenges and prospects in Chinese pharmaceutical regulatory environment

Development of Drug Design in China:40 Years of Achievements

The Impact of Generic Drug Entry on Market Shares and Prices of Brand-Name Drugs– Evidence from Chinese Pharmaceutical Market